Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2025-04-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
2024年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the year 2024, including amounts, balances, and related accounting subjects. It is a financial disclosure related to related party transactions and fund usage, typical of regulatory compliance disclosures in annual or periodic reports. However, it does not contain comprehensive financial statements or management discussion and analysis. It is a specific financial summary table rather than a full annual or interim report. Given the nature and detail, it fits best as a Regulatory Filing (RNS) because it is a compliance disclosure document that does not constitute a full financial report like an Annual Report (10-K) or Interim Report (IR).
2025-04-20 Chinese
2024年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the storage and use of raised funds for the year 2024 by 恩威医药股份有限公司. It details the amount of funds raised, their allocation, usage during the year, interest income, and changes in investment projects. It references regulatory requirements related to fundraising and fund management, and includes detailed financial figures about the raised funds and their use. The document is not a full annual report or interim report but a specific report focused on the management and use of capital raised from a public offering. This matches the description of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length (over 14,000 characters) and detailed financial data confirm it is a substantive report, not merely an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2025-04-20 Chinese
信永中和会计师事务所（特殊普通合伙）关于恩威医药2024年度非经常性损益明细表的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed auditor's special explanation and a non-recurring profit and loss statement for the fiscal year 2024 of Enwei Pharmaceutical Co., Ltd. It includes audit opinions, references to Chinese regulatory standards, and detailed financial data related to non-recurring items. The document is signed by certified public accountants and contains substantive financial data and analysis. It is not a brief announcement or a certification letter but a specialized audit report related to financial statements. Therefore, it fits best under the category of Audit Report / Information (AR). The document length is 2049 characters, which is relatively short but contains detailed financial tables and auditor commentary, indicating it is a standalone audit-related report rather than a mere announcement or certification. FY 2024
2025-04-20 Chinese
董事会对独董独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a specialized opinion from the board regarding the independence of the company's independent directors, referencing regulatory guidelines for independent directors and their compliance. It does not contain financial statements, earnings data, or other financial report content. It is a governance-related disclosure about board members' independence. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-04-20 Chinese
关于举行2024年度暨2025年一季度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of an online performance explanation meeting (业绩说明会) for the 2024 annual and 2025 first quarter results. It invites investors to participate and submit questions in advance. The document does not contain actual financial data or detailed financial statements but rather serves as a notice for an upcoming event where such information will be discussed. The document length is short (720 characters), and it is clearly an announcement rather than the report or transcript itself. Therefore, it fits best under the category of Investor Presentation (IP), as it relates to a detailed presentation for investors focusing on financials and strategy, even though the actual presentation will occur later. It is not a Call Transcript (CT) because it is not the transcript of the call but an announcement of the call. It is not a Report Publication Announcement (RPA) because it does not mention the report being published or attached, only the meeting to discuss results.
2025-04-20 Chinese
关于公司会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in the company's accounting policies based on a new interpretation issued by the Ministry of Finance of China. It details the reasons for the change, the effective date, the impact on the company, and the approvals by the board and supervisory committee. The document is relatively short (1510 characters) and does not contain actual financial statements or detailed financial data. It is not a full annual or interim report, nor is it an audit report or earnings release. It is a regulatory announcement about accounting policy changes, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories and is a formal disclosure to comply with regulations.
2025-04-20 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.